Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Movement disorders
How do you counsel patients with Parkinson Disease who are interested in starting GLP-1 agonists for neuroprotective benefits?
Related Questions
What workup do you recommend for isolated postural and action tremors in a developmentally typical toddler?
What leads you to consider a non-oral form of levodopa for the treatment of Parkinson’s disease?
How would you prioritize physiotherapy and cognitive behavioral therapy for functional movement disorders in a resource-limited setting where access to both might be constrained?
How do you manage and adjust Parkinson’s medication if a patient has worsening orthostatic hypotension while being treated with carbidopa/levodopa?
How frequently does one see resting tremor in drug-induced Parkinsonism?
How do you do a levodopa trial in the outpatient setting?
What is your preferred VMAT2 inhibitor to treat tardive dyskinesia; tetrabenazine, valbenazine, or deutetrabenazine?
Which type of botulinum toxin do you use for the initial and sequential treatment of dystonia?
How do you treat depression symptoms in patients with Parkinson's disease?
What are the recommendations for considering deep brain stimulation in a patient with tremors and dementia or mild cognitive impairment?
